Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRNX NASDAQ:IMTX NASDAQ:KYMR NASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$44.93-1.8%$34.37$24.10▼$62.53$4.31B0.332.17 million shs1.37 million shsIMTXImmatics$10.36-5.0%$6.73$3.30▼$10.95$1.32B1.221.07 million shs1.22 million shsKYMRKymera Therapeutics$57.21+0.3%$47.00$19.44▼$59.00$4.08B2.26916,704 shs736,904 shsPTGXProtagonist Therapeutics$87.00+29.8%$60.08$33.31▼$93.25$4.17B2.21.02 million shs7.06 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals+2.99%+10.24%+25.37%+43.31%-9.74%IMTXImmatics+5.11%+24.86%+88.26%+82.58%-1.54%KYMRKymera Therapeutics+1.30%+1.82%+31.14%+28.19%+31.56%PTGXProtagonist Therapeutics+2.66%+3.17%+14.87%+26.49%+51.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRNXCrinetics Pharmaceuticals$44.93-1.8%$34.37$24.10▼$62.53$4.31B0.332.17 million shs1.37 million shsIMTXImmatics$10.36-5.0%$6.73$3.30▼$10.95$1.32B1.221.07 million shs1.22 million shsKYMRKymera Therapeutics$57.21+0.3%$47.00$19.44▼$59.00$4.08B2.26916,704 shs736,904 shsPTGXProtagonist Therapeutics$87.00+29.8%$60.08$33.31▼$93.25$4.17B2.21.02 million shs7.06 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRNXCrinetics Pharmaceuticals+2.99%+10.24%+25.37%+43.31%-9.74%IMTXImmatics+5.11%+24.86%+88.26%+82.58%-1.54%KYMRKymera Therapeutics+1.30%+1.82%+31.14%+28.19%+31.56%PTGXProtagonist Therapeutics+2.66%+3.17%+14.87%+26.49%+51.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRNXCrinetics Pharmaceuticals 2.71Moderate Buy$74.4565.71% UpsideIMTXImmatics 2.57Moderate Buy$13.6731.92% UpsideKYMRKymera Therapeutics 2.95Moderate Buy$61.267.08% UpsidePTGXProtagonist Therapeutics 2.83Moderate Buy$68.83-20.88% DownsideCurrent Analyst Ratings BreakdownLatest IMTX, KYMR, PTGX, and CRNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CRNXCrinetics PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IMTXImmaticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025KYMRKymera TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PTGXProtagonist TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.0010/7/2025PTGXProtagonist TherapeuticsJohnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$74.0010/1/2025KYMRKymera TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$53.00 ➝ $63.009/30/2025CRNXCrinetics PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$73.00 ➝ $87.009/30/2025KYMRKymera TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $68.009/29/2025CRNXCrinetics PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$65.00 ➝ $77.009/29/2025CRNXCrinetics PharmaceuticalsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$80.00 ➝ $88.00(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRNXCrinetics Pharmaceuticals$1.04M4,068.76N/AN/A$14.29 per share3.14IMTXImmatics$168.65M7.47$0.23 per share44.61$5.12 per share2.02KYMRKymera Therapeutics$47.07M86.90N/AN/A$12.90 per share4.43PTGXProtagonist Therapeutics$434.43M12.46$5.86 per share14.84$11.33 per share7.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRNXCrinetics Pharmaceuticals-$298.41M-$4.11N/AN/AN/AN/A-32.28%-29.45%11/6/2025 (Estimated)IMTXImmatics$16.47M-$0.65N/AN/AN/A-59.29%-15.60%-12.31%11/17/2025 (Estimated)KYMRKymera Therapeutics-$223.86M-$3.47N/AN/AN/A-616.03%-31.60%-27.12%10/30/2025 (Estimated)PTGXProtagonist Therapeutics$275.19M$0.70124.29N/AN/A24.88%8.12%7.41%11/6/2025 (Estimated)Latest IMTX, KYMR, PTGX, and CRNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025CRNXCrinetics Pharmaceuticals-$1.27N/AN/AN/A$0.39 millionN/A11/6/2025Q3 2025PTGXProtagonist Therapeutics-$0.59N/AN/AN/A$5.41 millionN/A10/30/2025Q3 2025KYMRKymera Therapeutics-$0.73N/AN/AN/AN/AN/A8/13/2025Q1 2025IMTXImmatics-$0.38-$0.66-$0.28-$0.66$13.05 million$6.48 million8/11/2025Q2 2025KYMRKymera Therapeutics-$0.83-$0.95-$0.12-$0.95$17.37 million$11.48 million8/7/2025Q2 2025CRNXCrinetics Pharmaceuticals-$1.13-$1.23-$0.10-$1.23$0.52 million$1.03 million8/6/2025Q2 2025PTGXProtagonist Therapeutics-$0.53-$0.55-$0.02-$0.55$8.32 million$5.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRNXCrinetics PharmaceuticalsN/A17.8017.80IMTXImmaticsN/A8.808.80KYMRKymera TherapeuticsN/A8.328.32PTGXProtagonist TherapeuticsN/A16.9716.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRNXCrinetics Pharmaceuticals98.51%IMTXImmatics64.41%KYMRKymera TherapeuticsN/APTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipCRNXCrinetics Pharmaceuticals4.60%IMTXImmatics3.30%KYMRKymera Therapeutics16.01%PTGXProtagonist Therapeutics4.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRNXCrinetics Pharmaceuticals21094.18 million89.84 millionOptionableIMTXImmatics260121.55 million117.54 millionOptionableKYMRKymera Therapeutics17071.50 million60.05 millionOptionablePTGXProtagonist Therapeutics12062.21 million59.16 millionOptionableIMTX, KYMR, PTGX, and CRNX HeadlinesRecent News About These CompaniesH.C. Wainwright Keeps Their Buy Rating on Protagonist Therapeutics (PTGX)October 10 at 2:22 PM | theglobeandmail.comProtagonist Therapeutics stock surges after J&J acquisition talks reportOctober 10 at 2:22 PM | za.investing.comJ&J reportedly in talks to buy ProtagonistOctober 10 at 2:22 PM | msn.comWhy Did Protagonist Therapeutics Stock Soar Today?October 10 at 2:22 PM | msn.comJohnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reportsOctober 10 at 11:25 AM | reuters.comJohnson & Johnson in Talks to Buy Protagonist TherapeuticsOctober 10 at 11:13 AM | wsj.comTruist Financial Sticks to Its Buy Rating for Protagonist Therapeutics (PTGX)October 10 at 9:20 AM | theglobeandmail.comProtagonist Therapeutics' (PTGX) "Sell (D+)" Rating Reaffirmed at Weiss RatingsOctober 10 at 6:21 AM | marketbeat.com5 Analysts Assess Protagonist Therapeutics: What You Need To KnowOctober 8 at 7:08 PM | benzinga.comHC Wainwright & Co. Reiterates Protagonist Therapeutics (PTGX) Buy RecommendationOctober 8 at 7:08 PM | msn.comProtagonist Therapeutics' (PTGX) Buy Rating Reiterated at HC WainwrightOctober 8 at 8:26 AM | marketbeat.comProtagonist Therapeutics price target raised to $74 from $62 at Clear StreetOctober 7 at 7:15 PM | msn.comProtagonist Therapeutics (PTGX): Evaluating Valuation After a 65% Year-to-Date Share Price SurgeOctober 7 at 2:14 PM | finance.yahoo.comProtagonist Therapeutics, Inc. $PTGX Shares Bought by State of Alaska Department of RevenueOctober 3, 2025 | marketbeat.com14,339 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Precision Wealth Strategies LLCOctober 2, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Shares Down 5.1% - What's Next?September 29, 2025 | marketbeat.com7,530 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Palumbo Wealth Management LLCSeptember 25, 2025 | marketbeat.comAssenagon Asset Management S.A. Increases Stock Position in Protagonist Therapeutics, Inc. $PTGXSeptember 25, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Director Sells $257,000.00 in StockSeptember 24, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Reaches New 12-Month High - Should You Buy?September 24, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Buy" from AnalystsSeptember 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMTX, KYMR, PTGX, and CRNX Company DescriptionsCrinetics Pharmaceuticals NASDAQ:CRNX$44.93 -0.83 (-1.81%) Closing price 04:00 PM EasternExtended Trading$44.18 -0.76 (-1.68%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Immatics NASDAQ:IMTX$10.36 -0.54 (-4.95%) Closing price 04:00 PM EasternExtended Trading$10.24 -0.12 (-1.11%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Kymera Therapeutics NASDAQ:KYMR$57.21 +0.19 (+0.33%) Closing price 04:00 PM EasternExtended Trading$57.18 -0.04 (-0.06%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Protagonist Therapeutics NASDAQ:PTGX$87.00 +19.96 (+29.77%) Closing price 04:00 PM EasternExtended Trading$88.46 +1.46 (+1.68%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
